, Volume 18, Issue 3 Supplement, pp 281-282
Date: 06 Jul 2011

Moving Away From Axillary Lymph Node Dissection Indicates Practice-Changing Trials

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Axillary lymph node dissection (ALND) during breast-conserving surgery (BCS) or mastectomy has been the standard practice for the surgical treatment of breast cancer. To reduce side effects of ALND, sentinel lymph node dissection (SLND) has been developed and standardized for early-stage breast cancer. Until recently, micrometastases or metastases in one or more sentinel nodes was considered as indication for ALND. However, recent, large-scale, randomized trials have showed no survival benefit or improved locoregional control of ALND compared with no ALND when micrometastatic or metastatic disease is detected in sentinel lymph nodes (SLN).1,2 Therefore, ALND can be considered an overtreatment in selected patients. Under these new practice-changing results, new recommendations for multidisciplinary treatment of early breast cancer also require modification.

To highlight potential consequences by omitting complete ALND (cALND) after the publication of the American College of Surgeons Onco ...